Chemed (CHE) to Announce Quarterly Earnings on Tuesday

Chemed (NYSE:CHE) is expected to be releasing its Q2 2026 results after the market closes on Tuesday, July 28th. Analysts expect the company to announce earnings of $5.55 per share and revenue of $665.0360 million for the quarter. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a return on equity of 27.18% and a net margin of 10.23%.The firm had revenue of $657.51 million for the quarter, compared to the consensus estimate of $659.22 million. During the same quarter in the previous year, the business earned $5.63 EPS. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. On average, analysts expect Chemed to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Chemed Price Performance

CHE opened at $513.83 on Tuesday. The stock’s 50-day moving average price is $452.22 and its 200 day moving average price is $431.48. Chemed has a 12-month low of $365.20 and a 12-month high of $517.74. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 1.88 and a beta of 0.52. The company has a current ratio of 0.85, a quick ratio of 0.83 and a debt-to-equity ratio of 0.11.

Chemed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a dividend of $0.60 per share. The ex-dividend date was Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio is 13.08%.

Insider Activity at Chemed

In related news, Director Andrea R. Lindell sold 1,347 shares of the stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director directly owned 4,578 shares of the company’s stock, valued at $2,047,876.74. This trade represents a 22.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total transaction of $842,260.00. Following the sale, the chief executive officer owned 90,219 shares in the company, valued at $37,993,927.47. This represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.33% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Chemed

Several hedge funds have recently made changes to their positions in CHE. Los Angeles Capital Management LLC acquired a new stake in shares of Chemed during the fourth quarter worth about $26,000. Global Retirement Partners LLC lifted its holdings in shares of Chemed by 200.0% in the 4th quarter. Global Retirement Partners LLC now owns 87 shares of the company’s stock valued at $37,000 after purchasing an additional 58 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Employees Retirement System of Texas purchased a new position in Chemed during the 3rd quarter worth approximately $64,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in Chemed by 5,333.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 163 shares of the company’s stock worth $73,000 after buying an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Analysts Set New Price Targets

CHE has been the subject of several recent research reports. Wall Street Zen lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Bank of America raised their price target on shares of Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th. Weiss Ratings upgraded shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday. Finally, Royal Bank Of Canada upped their price objective on Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $480.25.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.